W
Wolf H. Fridman
Researcher at University of Paris
Publications - 551
Citations - 60835
Wolf H. Fridman is an academic researcher from University of Paris. The author has contributed to research in topics: Immune system & Receptor. The author has an hindex of 97, co-authored 525 publications receiving 48713 citations. Previous affiliations of Wolf H. Fridman include Queen Elizabeth Hospital Birmingham & Pasteur Institute.
Papers
More filters
Journal ArticleDOI
Les cellules B et les structures lymphoïdes tertiaires intra-tumorales sont des marqueurs de survie et de réponse à l’immunothérapie
Proceedings ArticleDOI
Abstract 4045: A novel transcriptomic-based immune classification of soft tissue sarcoma (STS) and its association with molecular characteristics, clinical outcome and response to therapy
Florent Petitprez,Tom Wei-Wu Chen,Cheng-Ming Sun,Julien Calderaro,Li-Ping Hsiao,Laetitia Lacroix,Ivo Natario,Maud Toulmonde,Carlo Lucchesi,Yec'han Laizet,Antoine Italiano,Aurélien de Reyniès,Catherine Sautès-Fridman,Wolf H. Fridman +13 more
TL;DR: A novel transcriptomic-based immune classification of soft tissue sarcoma (STS) and its association with molecular characteristics, clinical outcome and response to therapy is established.
Journal Article
Activation of effector functions by immune complexes of mouse IgG2a with isotype-specific autoantibodies
Éva Rajnavölgyi,György Fazekas,Lund J,Daeron M,Teillaud Jl,Jefferis R,Wolf H. Fridman,János Gergely +7 more
TL;DR: Analysis of five monoclonal autoantibodies, rheumatoid factors produced by hybridomas generated from spleen cells of BALB/c mice repeatedly infected with A/PR/8/34 human influenza A virus, revealed that they recognized distinct but spatially related epitopes, suggesting that the epitopes recognized are within the CH2 domain.
Journal Article
Problems and prospects of new immunotherapeutic approaches.
Wolf H. Fridman,Claire Mathiot,Jean Michon,Jean-Luc Teillaud,Thierry Dorval,Jean-Michel Zucker,Pierre Pouillart +6 more
TL;DR: The development of these new immunotherapeutic approaches will depend on the quality of their scientific bases, the clinical follow-up of the toxic effects, and the social management of the costs.